|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-18
|
|
pubmed:abstractText |
Psychomotor impairment has been described in hypertyrosinemia types II and III (HT III). Only recently cognitive deficits have also been reported in hypertyrosinemia type I (HT I). The pathogenic mechanisms responsible are unknown. Since implementation of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC, Nitisinone (Swedish Orphan International)) in the treatment of HT I, plasma tyrosine elevation is a common finding as known from the other hypertyrosinemias.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1096-7206
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
102
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
122-5
|
|
pubmed:meshHeading |
pubmed-meshheading:21112803-Brain,
pubmed-meshheading:21112803-Child,
pubmed-meshheading:21112803-Cyclohexanones,
pubmed-meshheading:21112803-Enzyme Inhibitors,
pubmed-meshheading:21112803-Humans,
pubmed-meshheading:21112803-Infant,
pubmed-meshheading:21112803-Male,
pubmed-meshheading:21112803-Nitrobenzoates,
pubmed-meshheading:21112803-Psychomotor Performance,
pubmed-meshheading:21112803-Serotonin,
pubmed-meshheading:21112803-Tyrosine,
pubmed-meshheading:21112803-Tyrosinemias
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I.
|
|
pubmed:affiliation |
Department of General Pediatrics, University Children's Hospital, Heinrich-Heine-University Düsseldorf, Moorenstrasse 5, Düsseldorf, Germany. Eva.Thimm@med.uni-duesseldorf.de
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
